BioSpace News Archive

GlycoMimetics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to purchase an aggregate of 150,000 shares to Chinmaya Rath, the Company’s new Senior Vice President and Chief Business Officer.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx’s proprietary anti-PSMA ADC, in prostate cancer patients.

HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, announced that Ahmad Masri, M.D., M.S. and Cedric Feschotte, Ph.D. are joining HAYA’s advisory boards.

Natera, Inc. announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program that Natera’s Signatera molecular residual disease test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT).

Helocyte, Inc. announced that data from a Phase 1 pilot trial evaluating the potential safety, immunological response and efficacy of the cytomegalovirus vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic cell transplants will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19, 2023, in Orlando, Florida.

Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2022 and provided first full year 2023 sales guidance.

Q4 2022 marked the conclusion of a transformational year for IRRAS, and, as we begin the new year, we have created new opportunities that will accelerate our growth toward achieving leadership in the world of neurocritical care.

Oxford Nanopore Technologies announced an extension of its collaboration with UPS Healthcare to accelerate the delivery of Oxford Nanopore DNA/RNA sequencing products and consumables across the Asia Pacific region.

Indivior PLC announced 2022 Full Year Results.